ARWR (Arrowhead Pharmaceuticals) Institutional Ownership: 96.70% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $72.78
GF Value $50.62
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Institutional Ownership?

Arrowhead Pharmaceuticals ARWR -1.83% 49 Institutional Ownership is 96.70% as of Jul. 14, 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $50.62 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arrowhead Pharmaceuticals's institutional ownership is 96.70%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arrowhead Pharmaceuticals's Insider Ownership is 5.89%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arrowhead Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 71.80%.

Arrowhead Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Institutional Ownership Chart

Arrowhead Pharmaceuticals Historical Data

The historical data trend for Arrowhead Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 49.35 50.50 51.95 53.37 54.10 51.94 56.52 57.35 57.63 55.91
ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 96.70% mean?
Arrowhead Pharmaceuticals (ARWR) has a Institutional Ownership of 96.70% as of Jul. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Institutional Ownership too high?
Arrowhead Pharmaceuticals' current Institutional Ownership is 96.70%. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Institutional Ownership compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Institutional Ownership of 96.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Institutional Ownership is 96.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $50.62, compared to a current price of $72.78 — trading 43.8% above its estimated fair value. The current Institutional Ownership is 96.70%. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Institutional Ownership is 96.70% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $72.78 is trading 43.8% above its estimated GF Value™ of $50.62. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Institutional Ownership: 96.70%
  • GF Value™: $50.62 vs. price of $72.78 (43.8% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$72.78
Price
$50.62
GF Value